Keyphrases
Abnormal Regulation
12%
Acute Myeloid Leukemia
32%
Acute Promyelocytic Leukemia
12%
Antibody-antigen
14%
Antibody-drug Conjugate
14%
Antitumor Effect
13%
B-cell non-Hodgkin Lymphoma (B-NHL)
12%
Bispecific Antibody
14%
Brentuximab Vedotin
15%
Cell Differentiation
14%
Cell Response
36%
Chimeric Antigen Receptor T Cells (CAR-T)
24%
Clinical Trials
23%
Diffuse Large B-cell Lymphoma (DLBCL)
16%
DNA Methyltransferase 3a
24%
DNMT3A
49%
DNMT3A mutation
16%
Donor-derived
13%
Eomes
12%
Filamentary Structure
12%
Fludarabine
13%
Follicular Lymphoma
24%
Form-Active
12%
Haploidentical Hematopoietic Stem Cell Transplantation
13%
Haploinsufficiency
12%
Hematopoietic Cell Transplantation
18%
Hematopoietic Cells
16%
Histone Methylation
12%
Human NK Cells
24%
Identity Function
12%
Interleukin-12 (IL-12)
21%
Interleukin-15 (IL-15)
20%
Interleukin-18 (IL-18)
15%
Iron Metabolism
12%
Leukemia
25%
Lymphoma
15%
Melphalan Conditioning
12%
Memory-like
86%
Mutational Landscape
12%
Natural Killer Cells
100%
NK Cell Activity
14%
Peripheral Blood
12%
Polarity Function
12%
Recent Advances
12%
Relapsed or Refractory
19%
Relapsed or Refractory Acute Myeloid Leukemia
13%
Subgroup Analysis
24%
T Cells
16%
Ultra-deep Sequencing
12%
Working Diagnosis
12%
Medicine and Dentistry
Acute Myeloid Leukemia
31%
Acute Promyelocytic Leukemia
12%
Antibody-Drug Conjugate
14%
B Cell
20%
Belinostat
12%
Bispecific Antibody
14%
Cancer Immunotherapy
12%
Cancer Pathobiology
12%
CD8 Antigen
12%
Cell Activation
12%
Cell Differentiation
15%
Cell Polarity
12%
Cell Transplantation
17%
Chimeric Antigen Receptor
12%
Chimeric Antigen Receptor T-Cell
12%
Chimeric Protein
12%
Classical Hodgkin Lymphoma
12%
Clinical Trial
35%
Colorectal Carcinoma
12%
Diffuse Large B-Cell Lymphoma
15%
DNA Methyltransferase 3A
36%
Follicular Lymphoma
24%
Granulocyte
12%
Haploinsufficiency
12%
Head and Neck Cancer
12%
Head and Neck Squamous Cell Carcinoma
12%
Hematopoietic Cell
31%
Histone Demethylation
12%
Interleukin 12
14%
Melanoma
12%
Microtubule
12%
Myeloid Malignancy
12%
Natural Killer Cell
91%
Natural Killer Cell Response
24%
Neoplasm
15%
Non-Hodgkin Lymphoma
12%
Oncology
12%
Patient with Leukemia
13%
Pediatrics Patient
12%
Polatuzumab Vedotin
14%
Pralatrexate
12%
Protein Complex
12%
Reproducibility
12%
Subgroup Analysis
24%
Systematic Review
24%
T Cell
14%
T-Cell Lymphoma
12%
Tetramer
12%
Transplantation
12%
Tumor Differentiation
12%
Immunology and Microbiology
B Cell
19%
Brain Tissue
12%
Cancer Immunotherapy
12%
CD8
12%
Cell Activation
13%
Cell Transplantation
24%
Cetuximab
6%
Chimeric Antigen Receptor
12%
Conditioning
14%
Cyclophosphamide
12%
Cytokine
16%
Cytotoxicity
6%
DNA Template
12%
Electron Microscopy
12%
Exome
8%
Haploinsufficiency
12%
Hematopoietic Cell
36%
Interleukin 12
17%
Interleukin 15
7%
Interleukin 18
5%
Multiple Myeloma
6%
Myeloid
14%
Natural Killer Cell
92%
Natural Killer Cell Response
24%
Neck
12%
Neoantigen
12%
Overall Survival
6%
Protein Complex
12%
Reed Sternberg Cell
12%
RNA Sequence
15%
Single Nucleotide Polymorphism
8%
Smoldering Multiple Myeloma
12%
Somatic Mutation
5%
Squamous Cell
9%
T Cell
17%
Tumor Vaccine
12%
Whole Exome Sequencing
15%